 |
인쇄하기
취소
|
Generic Baraclude developers queue up, but may have to wait
As the patent for Bristol-Myers Squibb (BMS)’s Baraclude (entecavir) is to expires in 2015, Korean pharmaceutical companies are gearing up to push generics into the market.
According to the Korea Food and Drug Administration, a total of 47 companies have applied for the administration's approval to manufacture Baraclude generics.
Observers say the looming expiration of the Baraclude paten...
According to the Korea Food and Drug Administration, a total of 47 companies have applied for the administration's approval to manufacture Baraclude generics.
Observers say the looming expiration of the Baraclude paten...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.